PTCT vs BMRN Stock Comparison: AI Score, Valuation, Performance and Upside
PTC Therapeutics and BioMarin both build their businesses around treating rare genetic disorders, but BioMarin has a longer track record and broader portfolio of approved therapies, while PTC Therapeutics is earlier in scaling its gene therapy and Duchenne-focused pipeline.
PTCT offers exposure to an earlier-stage rare disease pipeline with turnaround potential, while BMRN offers a more established, diversified rare disease commercial base. The decision hinges on whether you prefer BioMarin's broader approved portfolio or PTC's earlier-stage growth optionality.
PTCT holds the edge across 3 of 5 key metrics in this comparison. BMRN leads on both 1-year return (+7.48%) and forward P/E quality (10.20x vs 28.72x for PTCT), a relatively favorable combination of momentum and valuation. PTCT leads on both revenue growth (101.50%) and operating margin (41.32%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies similar upside for both: +38.30% for PTCT and +36.51% for BMRN.
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want exposure to a pipeline-driven rare disease biotech with gene therapy optionality
- Believe Duchenne muscular dystrophy treatments represent an underpenetrated therapeutic category
- Are comfortable with the concentration risk of a smaller rare disease commercial base
- See global expansion of existing rare disease franchises as a durable growth driver
- Prefer a rare disease biotech with a longer track record of commercial execution
- Value diversification across multiple approved rare disease therapies rather than reliance on a single franchise
- Believe achondroplasia and enzyme replacement franchises still have room to grow
- Want exposure to rare disease biotech without the binary risk of an unapproved gene therapy pipeline
| Metric | PTCT | BMRN |
|---|---|---|
| AI scorei | 61.4 | 27.4 |
| AI ranki | #114 | #2367 |
| Latest closei | $59.97 | $57.49 |
| 1M returni | -7.43% | -3.98% |
| 3M returni | -11.82% | -5.10% |
| 6M returni | -7.95% | +6.64% |
| 1Y returni | -11.95% | +7.48% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | PTCT | BMRN |
|---|---|---|
| 1Y ago | $8.8K (-12.0%) started 2025-10-30 | $11.09K (+10.9%) started 2025-10-29 |
| 5Y ago | $15.25K (+52.5%) started 2021-11-01 | $7.26K (-27.4%) started 2021-10-29 |
| 10Y ago | $96.57K (+865.7%) started 2016-10-31 | $7.14K (-28.6%) started 2016-10-31 |
Hypothetical — past performance does not guarantee future results.
| Metric | PTCT | BMRN |
|---|---|---|
| Market capi | $5.99B | $12.91B |
| Trailing P/Ei | N/A | 180.24 |
| Forward P/Ei | 28.72 | 10.20 |
| Price/Salesi | N/A | N/A |
| EV/Revenuei | 6.62 | 4.66 |
| Analyst targeti | $99.29 | $91.04 |
| Target upsidei | +38.30% | +36.51% |
| Metric | PTCT | BMRN |
|---|---|---|
| Revenue growthi | 101.50% | 19.90% |
| Earnings growthi | N/A | -81.30% |
| EPS growthi | N/A | -81.30% |
| FCF margini | -28.43% | +2.50% |
| Operating margini | 41.32% | 21.16% |
| Profit margini | -3.81% | 2.14% |
| ROIC proxyi | N/A | 1.18% |
| Return on equityi | N/A | 1.18% |
| Dividend yieldi | N/A | N/A |
| Payout ratioi | 0.00% | 0.00% |
| Dividend growth streaki | N/A | N/A |
| Betai | 0.55 | 0.23 |
| Debt/equityi | N/A | 66.47 |
| Current ratioi | 3.39 | 2.39 |
| Quick ratioi | 3.20 | 1.16 |
Over the past year, PTCT and BMRN have moved weakly in the same direction (correlation of 0.33), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | PTCT | BMRN |
|---|---|---|---|
| 1Y | Growthi | -11.95% | +10.86% |
| CAGRi | -11.96% | +10.87% | |
| Volatilityi | 41.35% | 35.29% | |
| Sharpe ratioi | -0.21 | 0.34 | |
| Sortino ratioi | -0.30 | 0.60 | |
| Max drawdowni | 33.85% | 22.58% | |
| Current drawdowni | 33.03% | 18.15% | |
| Avg drawdowni | 16.68% | 9.17% | |
| Ulcer Indexi | 18.75% | 11.03% | |
| Max daily dropi | 9.94% | 4.35% | |
| Max wkly dropi | 12.49% | 8.75% | |
| 5Y | Growthi | +52.52% | -27.44% |
| CAGRi | +8.82% | -6.21% | |
| Volatilityi | 55.08% | 32.76% | |
| Sharpe ratioi | 0.35 | -0.17 | |
| Sortino ratioi | 0.51 | -0.25 | |
| Max drawdowni | 69.42% | 57.64% | |
| Current drawdowni | 33.03% | 50.98% | |
| Avg drawdowni | 23.94% | 30.30% | |
| Ulcer Indexi | 29.53% | 35.09% | |
| Max daily dropi | 29.77% | 17.71% | |
| Max wkly dropi | 39.59% | 17.74% | |
| 10Y | Growthi | +865.70% | -28.60% |
| CAGRi | +25.47% | -3.32% | |
| Volatilityi | 63.44% | 35.06% | |
| Sharpe ratioi | 0.59 | -0.04 | |
| Sortino ratioi | 0.93 | -0.06 | |
| Max drawdowni | 73.78% | 62.09% | |
| Current drawdowni | 33.03% | 56.12% | |
| Avg drawdowni | 26.83% | 30.39% | |
| Ulcer Indexi | 31.98% | 34.84% | |
| Max daily dropi | 32.96% | 35.28% | |
| Max wkly dropi | 39.59% | 38.91% |
| Category | PTCT | BMRN |
|---|---|---|
| Company | PTC Therapeutics, Inc. | BioMarin Pharmaceutical Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| Core business | A biopharmaceutical company focused on treatments for rare genetic disorders, including Duchenne muscular dystrophy therapies and gene therapy programs for neurological and metabolic conditions. | A biotechnology company specializing in therapies for rare genetic diseases, with an established portfolio addressing phenylketonuria, achondroplasia, and other inherited metabolic and skeletal conditions. |
| Investor focus | Commercial uptake of approved rare disease therapies, regulatory milestones for pipeline gene therapy candidates, and royalty or partnership revenue contribution. | Growth of newer franchise launches, pricing and access dynamics for high-cost rare disease drugs, and pipeline expansion into adjacent rare disease indications. |
- Established commercial presence in Duchenne muscular dystrophy gives the company a foothold in a niche but high-need treatment category
- Diversified pipeline spanning gene therapy and small-molecule approaches spreads regulatory and clinical risk across multiple modalities
- Global commercial infrastructure supports launches across both US and international rare disease markets
- Longer operating history in rare disease drug development has produced a broader base of approved, revenue-generating therapies
- Leadership position in achondroplasia treatment addresses a condition with limited historical treatment options
- Scale advantages in manufacturing and global distribution support consistent supply for chronically dependent patient populations
- Regulatory setbacks or label restrictions on rare disease therapies can materially affect commercial trajectories given the smaller patient populations involved
- Reliance on a concentrated set of rare disease franchises leaves earnings more exposed to any single product's performance
- Payer negotiations for high-priced rare disease treatments can pressure realized pricing and reimbursement timelines
- Maturing legacy products may see slower growth as newer competitors and biosimilar-like alternatives emerge over time
- Rare disease drug pricing remains a recurring target for policy scrutiny and payer pushback
- Pipeline expansion into new indications carries the typical binary risk of clinical trial outcomes
Compare more than two at a time
This page is a fixed writeup on PTCT and BMRN. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside PTCT and BMRN, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.